The only Food and Drug Administration (FDA)-approvedmedications for the Leishmaniasis treatment are intravenous liposomalamphotericin B (L-AmB) for VL and oral miltefosine for CL, ML, and VL caused byparticular species. Leishmaniasis is parasitic disease caused due to aninfection with Leishmania parasites and transmitted through the bite ofinfected female phlebotomine sand flies. There are several different forms ofLeishmaniasis. The most common forms are visceral Leishmaniasis, which affectsseveral internal organs (usually liver, spleen, and bone marrow), cutaneousLeishmaniasis, which causes skin sores, and mucocutaneous Leishmaniasis, Visceralis the most serious condition among the other two forms.
According to the World Health Organization, Leishmaniasis isa curable and treatable disease, which requires an immunocompetent systembecause medicines will not get rid of the parasite from the body, thus the riskof relapse if immunosuppression occurs. The first of the four differentLeishmaniasis treatments, called antifungal agents, is lecithin. It works bypreventing inflammation and infection of capillaries. Studies have shown thatthis agent is effective in treating cutaneous candidiasis but may causehypopigmentation (darkening of skin). This is a cosmetic problem that does notinterfere with daily life. It responds well to systemic steroids.
The second new Leishmaniasistreatment is miltefosine. Miltefosine is a type of monoclonalimmunomodulator protein that has been shown to be efficient against a widerange of fungal infections, including Leishmaniasis. It is usually administeredonce a day. The third new Leishmaniasis treatment is pentavalent antimonials.These antimony compounds are similar in composition to insulin. They stimulatethe pancreas to secrete more blood insulin, which help reduce the amount ofglucose in the bloodstream and, over time, prevents the disease from becomingchronic. It is available under various names.
Read More : https://bit.ly/3yB1WDY
